Febuxostat in the treatment of patients 
with gout in light of the FAST study

Michał Holecki

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

2/2021
vol. 7

Send email

Copy url:

abstract:

Febuxostat in the treatment of patients with gout in light of the FAST study

Michał Holecki

¹

Klinika Chorób Wewnętrznych, Autoimmunologicznych i Metabolicznych, Śląski Uniwersytet Medyczny w Katowicach

Online publish date: 2021/05/22

View full text Get citation

Gout, due to its frequency and concomitant chronic complications, is a significant social and therapeutic problem. Current guidelines explicitly recommend the use of urate-lowering drugs only in patients diagnosed with gout. Such an indication does not raise any doubts. Despite the lack of conclusive evidence or recommendations, hypouricaemic therapy, especially allopurinol, is widely used in patients with asymptomatic hyperuricaemia despite the risk of potentially life-threatening hypersensitivity reactions. The article discusses selected issues related to the treatment of patients with hyperuricaemia, both related and unrelated to gout, compares febuxostat with allopurinol, and presents the results of studies on cardiovascular risk during urate-lowering treatment, including the latest FAST study.

keywords:

Febuxostat in the treatment of patients with gout in light of the FAST study

Michał Holecki 1

hyperuricaemia, gout, treatment, adverse effects

Michał Holecki

¹